Pancreatic Cancer Research

ResearcherVita-Salute San Raffaele UniversityActive in the last 2 years

Lorenzo Piemonti

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-2172-2198; OpenAlex author ID A5005129014. Sources: OpenAlex.

Their work

Papers
23 (first author 1, last author 12)
Trials
0
Grants
0
Labs led
1
Collaborators
57
Papers, trials and grants by year

2011: 1 paper · 2012: 2 papers · 2013: 1 paper · 2014: none · 2015: none · 2016: 4 papers · 2017: 2 papers · 2018: 3 papers · 2019: 1 paper · 2020: 2 papers · 2021: 1 paper · 2022: 2 papers · 2023: 1 paper · 2024: 2 papers · 2025: none · 2026: 1 paper

Papers 23

  1. An oncogenic KRAS-driven secretome involving TNFα promotes niche preparation prior to pancreatic cancer onset. Co-author DOI 10.1186/s12943-025-02541-1↗
  2. Establishment of a Transplantation Model of PDAC-Derived Liver Metastases. Last author DOI 10.1245/s10434-024-15514-3↗
  3. ASO Author Reflections: Bridging the Gap in PDAC Research: The Intraportal Model as a Platform for Studying Preclinical Liver Metastasis. Last author DOI 10.1245/s10434-024-15655-5↗
  4. IL-1β+ macrophages fuel pathogenic inflammation in pancreatic cancer. Co-author DOI 10.1038/s41586-023-06685-2↗
  5. Interrupting the nitrosative stress fuels tumor-specific cytotoxic T lymphocytes in pancreatic cancer. Co-author DOI 10.1136/jitc-2021-003549↗
  6. A Comprehensive Characterization of Stemness in Cell Lines and Primary Cells of Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/ijms231810663↗
  7. The Extracellular Matrix in Pancreatic Cancer: Description of a Complex Network and Promising Therapeutic Options. Last author DOI 10.3390/cancers13174442↗
  8. B lymphocytes contribute to stromal reaction in pancreatic ductal adenocarcinoma. Co-author DOI 10.1080/2162402x.2020.1794359↗
  9. Circulating Chromogranin A Is Cleaved Into Vasoregulatory Fragments in Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fonc.2020.613582↗
  10. Glucose metabolism during tumorigenesis in the genetic mouse model of pancreatic cancer. Last author DOI 10.1007/s00592-019-01335-4↗
  11. Gene expression analysis of embryonic pancreas development master regulators and terminal cell fate markers in resected pancreatic cancer: A correlation with c… Last author DOI 10.1016/j.pan.2018.09.006↗
  12. Four-class tumor staging for early diagnosis and monitoring of murine pancreatic cancer using magnetic resonance and ultrasound. Last author DOI 10.1093/carcin/bgy094↗
  13. No evidence of pancreatic ductal adenocarcinoma specific autoantibodies to Ezrin in a liquid phase LIPS immunoassay. Co-author DOI 10.3233/cbm-181218↗
  14. A preoperative score to predict early death after pancreatic cancer resection. Last author DOI 10.1016/j.dld.2017.06.012↗
  15. Modeling the Iatrogenic Pancreatic Cancer Risk After Islet Autotransplantation in Mouse. Last author DOI 10.1111/ajt.14360↗
  16. Phase II trial of salvage therapy with trabectedin in metastatic pancreatic adenocarcinoma. First author DOI 10.1007/s00280-015-2932-3↗
  17. Diabetes associated with pancreatic ductal adenocarcinoma is just diabetes: Results of a prospective observational study in surgical patients. Last author DOI 10.1016/j.pan.2016.08.005↗
  18. (Ir)relevance of Metformin Treatment in Patients with Metastatic Pancreatic Cancer: An Open-Label, Randomized Phase II Trial. Last author DOI 10.1158/1078-0432.ccr-15-1722↗
  19. Effect of Diabetes on Survival after Resection of Pancreatic Adenocarcinoma. A Prospective, Observational Study. Last author DOI 10.1371/journal.pone.0166008↗
  20. Mass spectrometric analysis reveals O-methylation of pyruvate kinase from pancreatic cancer cells. Co-author DOI 10.1007/s00216-013-6880-7↗
  21. MS analysis reveals O-methylation of L-lactate dehydrogenase from pancreatic ductal adenocarcinoma cells. Co-author DOI 10.1002/elps.201200017↗
  22. Proteomic analysis reveals Warburg effect and anomalous metabolism of glutamine in pancreatic cancer cells. Co-author DOI 10.1021/pr2009274↗
  23. Proteomic analysis of pancreatic ductal adenocarcinoma cells reveals metabolic alterations. Co-author DOI 10.1021/pr101179t↗

Closest collaborators

The 25 strongest of 57 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Erica Dugnani · 18 shared papers, 2013–2024 · strength 1.63
  2. Claudio Doglioni · 11 shared papers, 2016–2024 · strength 0.97
  3. Benedetta Ferrara · 5 shared papers, 2021–2026 · strength 0.92
  4. Valentina Pasquale · 10 shared papers, 2016–2022 · strength 0.74
  5. Michele Reni · 9 shared papers, 2016–2022 · strength 0.66
  6. Massimo Falconi · 9 shared papers, 2016–2023 · strength 0.65
  7. Paolo Riccardo Camisa · 3 shared papers, 2024–2026 · strength 0.60
  8. Gianpaolo Balzano · 8 shared papers, 2016–2022 · strength 0.58
  9. Marco Schiavo Lena · 3 shared papers, 2023–2024 · strength 0.52
  10. Daniela Liberati · 8 shared papers, 2016–2019 · strength 0.52
  11. Stefano Crippa · 4 shared papers, 2017–2026 · strength 0.45
  12. Francesco Novelli · 5 shared papers, 2011–2023 · strength 0.24
  13. Vincenzo Corbo · 2 shared papers, 2022–2023 · strength 0.22
  14. Vito Lampasona · 3 shared papers, 2016–2018 · strength 0.20
  15. Chantal Allgöwer · 1 shared paper, 2026 · strength 0.19
  16. Élodie Roger · 1 shared paper, 2026 · strength 0.19
  17. Claus Jørgensen · 1 shared paper, 2026 · strength 0.19
  18. Michael Karl Melzer · 1 shared paper, 2026 · strength 0.19
  19. Dharini Srinivasan · 1 shared paper, 2026 · strength 0.19
  20. Anton Lahusen · 1 shared paper, 2026 · strength 0.19
  21. Alexander Kleger · 1 shared paper, 2026 · strength 0.19
  22. Thomas Theodor Werner Seufferlein · 1 shared paper, 2026 · strength 0.19
  23. Maria Pia Protti · 2 shared papers, 2020 · strength 0.18
  24. Francesco De Sanctis · 2 shared papers, 2018–2022 · strength 0.17
  25. Michela Capello · 4 shared papers, 2011–2013 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.